GBT Global Blood Therapeutics Inc.

53.82
+0.97  (+2%)
Previous Close 52.85
Open 53.11
Price To Book 4.59
Market Cap 3,230,195,670
Shares 60,018,500
Volume 528,776
Short Ratio
Av. Daily Volume 737,941

NewsSee all news

  1. GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease

    Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months NDA Supported by Data from Phase 3 HOPE Study, which Demonstrated Statistically Significant and Sustained Improvements in Hemoglobin with

  2. GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on September 1, 2019, the compensation committee of GBT's board of directors

  3. GBT Announces Participation at the 2019 Morgan Stanley Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 2019 Morgan Stanley Global Healthcare Conference in New

  4. GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

    Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream

  5. GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

    Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a discontinuation announced October 23, 2017 due to lack of efficacy.
GBT440
Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest
PDUFA date under priority review February 26, 2020.
Voxelotor
Sickle cell disease
Phase 2 data to be presented at ASH December 3, 2018 noted 55% (6 of 11) achieved a hemoglobin response >1 g/dL .
GBT440 HOPE-KIDS 1
Sickle cell disease - children age 6-17.

Latest News

  1. GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease

    Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months NDA Supported by Data from Phase 3 HOPE Study, which Demonstrated Statistically Significant and Sustained Improvements in Hemoglobin with

  2. GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on September 1, 2019, the compensation committee of GBT's board of directors

  3. GBT Announces Participation at the 2019 Morgan Stanley Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 2019 Morgan Stanley Global Healthcare Conference in New

  4. GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

    Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream

  5. GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

    Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream